University Of California, San Francisco

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Modifiers of Disease Severity in Cerebral Cavernous Malformations

Recruiting

Conditions: Cavernous Angioma, Familial
Cerebral Cavernous Hemangioma
Cerebral Cavernous Malformations

First Posted Date: 2013-01-09

Last Posted Date: 2023-12-26

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 800

Registration Number: NCT01764529

Locations: 🇺🇸
Barrow Neurological Institute, Phoenix, Arizona, United States
🇺🇸
University of Chicago, Medicine and Biological Sciences, Chicago, Illinois, United States
🇺🇸
Boston Children's Hospital, Boston, Massachusetts, United States

and more 4 locations

Effects of Gastric pH on the Pharmacokinetics of Atazanavir

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Ritonavir-boosted Atazanavir
Drug: Ritonavir-boosted Atazanavir plus Rabeprazole
Drug: Ritonavir-boosted Atazanavir plus Rabeprazole AND Betaine Hydrochloride

First Posted Date: 2013-01-03

Last Posted Date: 2015-04-28

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 8

Registration Number: NCT01759875

Locations: 🇺🇸
Clinical Research Center, UCSF, San Francisco, California, United States

Preoperative and Intraoperative Factors Related to the Development of Ptosis After Retinal Surgery

Completed

Conditions: Development of Ptosis After Vitreo-retinal Surgery

First Posted Date: 2012-12-19

Last Posted Date: 2016-05-20

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 50

Registration Number: NCT01752478

Locations: 🇺🇸
University of California, San Francisco, San Francisco, California, United States

Study of Hyperkyphosis, Exercise and Function-SHEAF

Not Applicable

Completed

Conditions: Kyphosis

Interventions: Other: Control
Behavioral: Kyphosis-specific spinal strengthening exercises

First Posted Date: 2012-12-18

Last Posted Date: 2023-03-07

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 99

Registration Number: NCT01751685

Locations: 🇺🇸
UCSF, San Francisco, California, United States

Topiramate Treatment of Hazardous and Harmful Alcohol Use in Veterans With TBI

Phase 4

Completed

Conditions: Traumatic Brain Injury (TBI)
Hazardous and Harmful Alcohol Use

Interventions: Behavioral: Medical Management Counseling
Drug: Placebo
Drug: Topiramate

First Posted Date: 2012-12-17

Last Posted Date: 2020-10-14

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 32

Registration Number: NCT01750268

Locations: 🇺🇸
San Francisco VA Medical Center, San Francisco, California, United States

The Influence of a Bupivacaine Digital Nerve Block Using Rev G.

Not Applicable

Completed

Conditions: Patients Undergoing Spine Surgery

Interventions: Other: intermediate-acting digital nerve block

First Posted Date: 2012-12-17

Last Posted Date: 2015-04-10

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 19

Registration Number: NCT01750554

Locations: 🇺🇸
University of California, San Francisco, San Francisco, California, United States

A Controlled Trial of Topiramate Treatment for Alcohol Dependence in Veterans With PTSD

Phase 4

Completed

Conditions: Alcohol Dependence
Posttraumatic Stress Disorder (PTSD)

Interventions: Drug: placebo
Drug: Topiramate
Behavioral: Medical Management

First Posted Date: 2012-12-13

Last Posted Date: 2021-06-21

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 151

Registration Number: NCT01749215

Locations: 🇺🇸
San Francisco VA Medical Center, San Francisco, California, United States

Vemurafenib in Children With Recurrent/Refractory BRAF Gene V600E (BRAFV600E)-Mutant Gliomas

Early Phase 1

Active, not recruiting

Conditions: Pediatric Recurrent/Refractory BRAFV600E-mutant Gliomas

Interventions: Drug: Vemurafenib

First Posted Date: 2012-12-12

Last Posted Date: 2024-01-17

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 40

Registration Number: NCT01748149

Locations: 🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸
Mattel Children's Hospital UCLA, Los Angeles, California, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

and more 18 locations

Phase2a Primaquine Dose Escalation Study

Phase 2

Completed

Conditions: Malaria

Interventions: Drug: dihydroartemisinin-piperaquine
Drug: 0.0625 mg/kg Primaquine
Drug: 0.25 mg/kg Primaquine
Drug: 0.125 mg/kg Primaquine
Drug: 0.5 mg/kg Primaquine

First Posted Date: 2012-12-06

Last Posted Date: 2015-01-19

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 81

Registration Number: NCT01743820

Locations: 🇲🇱
Malaria Research and Training Centre, Bamako, Mali

Neuroimaging Studies of Chronic Primary Headaches Using Positron Emission Tomography and Magnetic Resonance Imaging

Completed

Conditions: Chronic Migraine
Migraine

First Posted Date: 2012-12-04

Last Posted Date: 2015-06-30

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 78

Registration Number: NCT01741246

Locations: 🇺🇸
UCSF, San Francisco, California, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy